GTFRCC Members

University of Ibadan, Ibadan, Nigeria

National Centre for Cancer Care & Research, Doha, Qatar

Dr. Noora Al Hammadi

Dr. Noora Al Hammadi is the Chairman of the Department of Radiation Oncology and a Senior Consultant Radiation Oncologist at the National Centre for Cancer Care & Research. She is also an Assistant Professor, Clinical Radiation Oncology at the Weill Cornell Medical College.

Dr. Al Hammadi obtained her Bachelors in Medical Sciences from the Arabian Gulf University, Bahrain in 1997 and went on to obtain her MD degree in 1999. She undertook general professional training at HMC in Qatar before completing specialist training in Radiation Oncology at the University Clinics of Heidelberg in Germany. After obtaining her FACHARZT (German Board) in Radiation Oncology in 2008, she returned to HMC as a Staff Radiation Oncologist. She was appointed Chairman of the Radiation Oncology Department in 2009.
Dr. Al Hammadi has a subspecialty interest in Breast Radiation Oncology and she is a current member of the HMC Multidisciplinary Breast Cancer Site Group. She is also an active member of the senior leadership team at the NCCCR. In addition to her clinical and administrative responsibilities, Dr. Al Hammadi is the Qatar program manager for the International Atomic Energy Agency (IAEA) QUATRO program and she chairs several regional training programs in radiation oncology offered under the auspices of the IAEA. Her research interests are in the area of quality assurance in radiation oncology and the management of technology innovation in cancer care.

Gulf Ferderation for Cancer Control, Kuwait

Dr. Khalid Ahmed Al-Saleh

Khaled Ahmed AlSaleh (27th October, 1953) is Consultant of clinical and Head of Radiation Oncology in Kuwait Cancer Control Center (KCCC). He is also Editor of the Gulf Journal Oncology (GJO). GJO is the first international court Magazine Gulf and is published through the electronic library in PubMed & INDEX. www.gffcc.org/journal.

AlSaleh was born in Kuwait Almirqab. He obtained his M.B.B, Ch. at Alexandria on 14 February 1981, and his Board Certificate in Radiotherapy & Oncology from the Maria Skłodowska-Curie Institute of Oncology, Warsaw, Poland, in November 1992.

A total of 28 years in the field of oncology specializing in Radiation Oncology. Author of more than 30 scientific papers presented to international fora and published in medical journals.
Dr. Khalid Ahmed Al-Saleh has won Kuwait’s Prize for Cancer and Cardiovascular Diseases and diabetes granted by the World Health Organization (WHO) in the Eastern Mediterranean Region in recognition of his efforts in this area.

Current Positions:
1. General Secretary, The Gulf Federation for Cancer Control (www.gffcc.org ),
2. Vice-President, Board of CAN Campaign (Cancer Aware Nation), (www.cancampaignkw.com ), Jan. 2011 to date
3. Founder and Editor-in-Chief, The Gulf Journal of Oncology (www.gffcc.org/journal ), 2007 to date;
4. Associate Editor, Pan-Arab Medical Journal of Oncology, (http://amaac.org/05.htm), March 2008 to date
5. General Secretary, Kuwait Society for Smoking and Cancer Prevention, (1994 to date);

Breast Health Global Initiative, Seattle, United States

Dr. Ben Anderson

Dr. Anderson is Professor of Surgery and Global Health Medicine at the University of Washington (UW) in Seattle where his practice is devoted to caring for patients with breast health issues and cancer. Dr. Anderson’s clinical interests include oncoplastic breast surgery, which simultaneously improves oncologic and cosmetic outcomes with complex cancer resections. He holds joint faculty positions at the Fred Hutchinson Cancer Research Center Division of Public Health Sciences and the UW Department of Global Health. He directs the Breast Health Clinic at the Seattle Cancer Care Alliance (SCCA). From 2005-2007, Dr. Anderson served as President of the American Society of Breast Disease (ASBD).

Dr. Anderson created and chairs the Breast Health Global Initiative (BHGI), which developed resource-stratified guidelines for breast cancer early detection, diagnosis and treatment in low- and middle-income countries (LMICs). On the U.S. delegation to the 58th World Health Assembly in Geneva, Dr. Anderson contributed to the 2005 World Health Organization (WHO) Cancer Prevention and Control Resolution. The American Society of Clinical Oncology (ASCO) awarded Dr. Anderson their 2011 Partners in Progress Award. In 2012, Dr. Anderson was elected to the Board of Directors of the Union for International Cancer Control (UICC), the oldest international professional organization addressing global cancer control. Dr. Anderson now chairs the National Comprehensive Cancer Network (NCCN) International Program Committee. Most recently, the National Consortium of Breast Centers (NCBC) awarded him their 2013 Inspiration Award, recognizing his dedication and efforts to improve quality and effectiveness of breast cancer care around the globe.

AMPATH Oncology Institute, Eldoret, Kenya

University of Liverpool, Liverpool, United Kingdom

Dr. Riccardo Audisio

Riccardo A. Audisio was born in Milan, Italy and graduated in Padua (1980): he specialised in General Surgery (1985) and Diagnostic Radiology (1994).

Trained at the National Cancer Institute of Milan (1980-94) he was appointed deputy director at the Department of General Surgery, European Institute of Oncology, Milan (1994-8).

He moved to the United Kingdom in 1999 to become Consultant Surgical Oncologist and Honorary Professor at the University of Liverpool.

Editor-in-Chief of Surgical Oncology, Elsevier Publisher (2007-13) he is Editor of the European Journal of Surgical Oncology. Author of 197 peer-reviewed publications and 36 book chapters, Prof. Audisio edited 17 book projects and is guest reviewer for 37 international scientific journals.

Professor Audisio is member of several international scientific societies including BASO, ESSO, SSO, ASGBI, ESMO, ASCRS, AAA, SIOG and EUSOMA. He is ESMO Committee Member, past-chair of the Education & Training Committee of ESSO. He is BASO President and ESSO President-Elect. He served as an advisor to the Department of Health and to the All Party Parliamentary Group on Breast Cancer in Older Women.

His clinical research focuses on Breast Cancer and Geriatric Oncology; Immediate Past-President of SIOG (International Society of Geriatric Oncology) and past-chair the Surgical Task Force, Professor Audisio has organised several international advanced courses/meeting on geriatric-oncology.

Tata Memorial Hospital, Mumbai, India

University of Amsterdam, Amsterdam, Netherlands

Dr. Harry Bartelink

Harry Bartelink (1946) received his medical degree at the University of Nijmegen, and thereafter completed his residency at the NKI-AVL in Amsterdam. There he also worked on his PhD. Since then he has worked in several foreign locations: the Rotterdam Radiotherapeutic Institute, the Institut Gustave-Roussy, Villejuif, France; Stanford University, California USA first in 1981 as post doc, and again in 1984 as a visiting professor.

From 1985-2007, he was chairman of the Radiation Oncology Division at the NKI-AVL, responsible for patient care and scientific research (total staff 300) with particular interest in head and neck tumors and breast cancer. In 1990 he became extra-ordinary professor in Experimental Radiotherapy at the Free University of Amsterdam and moved this position to the University of Amsterdam in 1999. Since 2007, he is advisory member of the board of directors of the NKI-AvL, consultant at Institute Gustave Roussy in Villejuif and in 2008 became associate professor at the University of Paris.

He currently holds various honorary positions: amongst them honorary fellow of the American College of Radiology 1997, recipient of the ESTRO Breur Medal in1997, the Fletcher Award in 2000, Kligerman award in 2004, Antoine Béclère Medal in 2005. Kilroe Award, 2006. In 2007 Franz Buschke award and the Janeway Gold medal award from the American Radium Society. Doctora Honoris Causa at the University of Gdansk, 2008.

In April 2007 he was awarded the “Ridder in de Orde van de Nederlandse Leeuw” by the Queen of the Netherlands. In 2014 he was the recipient of the European Breast Science Award.

He is also a Board Member several European and American organizations and was from 1991-1996 chairman of the EORTC Radiotherapy Cooperative Group, from 2001-2003 president of European Society for Therapeutic Radiology and Oncology (ESTRO), and from 2003-2005 president of the European CanCer Organisation (ECCO) – formerly “Federation of European Cancer Societies” (FECS). Since 2012 has been coordinator of the large EU project ARTFORCE. Up to now, he has contributed to more than 300 peer reviewed publications.

University of South Wales, Sydney, Australia

Dr. Michael Barton

Michael Barton is Professor of Radiation Oncology at University of New South Wales in Sydney, Austraila. He is also Research Director of the Collaboration for Cancer Outcomes Research and Evaluation (CCORE) and the Research Director of the Ingham Institute at Liverpool Hospital. His major interest is in cancer health services research.

Technische Universität Dresden, Dresden, Germany

Dr. Michael Baumann

Michael Baumann is Professor of Radiation Oncology at Technische Universität Dresden (TUD). He is Director of the Interdisciplinary University Cancer Center, and Chairman of the OncoRay-Center for Radiation Research in Oncology. He was President the European Society for Therapeutic Radiology and Oncology (ESTRO) from 2003-2007. He is past President of ECCO – the European Cancer Organisation.

University of Maryland School of Medicine, Baltimore, United States

Dr. Søren M. Bentzen

Søren M. Bentzen, MSc, PhD, DMSc, Professor, University of Maryland School of Medicine (UMSOM), primary appt.: Epidemiology and Public Health, secondary appointment: Radiation Oncology; Director, Biostatistics Shared Service, Greenebaum Cancer Center, and Director, Division of Biostatistics and Bioinformatics, UMSOM since 2013. Dr. Bentzen is Adjunct Professor of Radiobiology and Medical Physics, University of Copenhagen. Previous appointments include MD Anderson Cancer Center (‘87-‘88); Danish Cancer Society/Aarhus University (‘88-‘97); Gray Laboratory/Mt Vernon Hospital, London (‘98-‘04); University of Wisconsin School of Medicine and Public Health (‘05-‘13).

Qualifications: MSc in physics and mathematics (‘81); PhD in medical image analysis (‘86); DMSc in quantitative clinical radiobiology (‘94), all from Aarhus University. He has published 386 original papers/book chapters and presented >300 invited lectures. Citation metrics (February ‘14): h-index: 62; >11,000 citations (ISI Web of Science); h-index: 76; >17,000 citations (Google Scholar).

Dr. Bentzen serves on 10 journal editorial boards. He has received 24 awards, including ESTRO’s Gold Medal (‘03); MD Anderson Distinguished Alumnus Award (‘08); Honorary Life Memberships of Assoc. of Radiation Oncologists of India (‘08) and Belgian Society for Therapeutic Radiology & Oncology (‘09). He was Honorary Professor, University College London (‘00-‘05) and Visiting Statistician, MRC Clinical Trials Office, London (‘98-‘04).

Dr. Bentzen is principal investigator of a phase III trial of resource sparing radiation therapy for locally-advanced head and neck cancer, sponsored by International Atomic Energy Agency; serves on numerous committees including the Previously-untreated Locally Advanced Disease Task Force, Head and Neck Cancer Steering Committee, National Cancer Institute; Board of Directors, International Commission on Radiation Units. He has served as chair or member of 17 (7 active) Independent Data and Safety Monitoring or Trial Steering Committees. He is Translational Research co-chair for two open RTOG phase III trials.

Assoication of Radiation Oncologist of India, Bangalore, India

Dr. Ramesh Bilimagga

Prof. Bilimagga, has Completed his M.D. in Radiotherapy from Bangalore Medical College under Bangalore University in 1982. He has received training in Nuclear Medicine from Radiation Medicine Center (BARC) Bombay. He has over 37 years of experience, in the field of radiation oncology.
He was a clinical observer in Norfolk Medical School, Virginia, USA,UCLA, California, USA, Long Beach Memorial Hospital, USA. Mount Sanai Hospital, Baltimore, USA. He is certified Cyber Knife Trained person by Accuray in U.S.A.

He is a Fellow of International College of Surgeons (Indian Section) and Fellow of Indian College of Radiation Oncology. His special areas of interest are HDR brachytherapy, Chemo-Radiation and Cyber Knife in Head & Neck Malignancy.

He is in the Editorial board of Journal of Cancer Research & Therapeutics India & Contemporary Brachytherapy of Polish Brachytherapy Society & JCRT, India.

He has received many awards for his work in the field of Radiation Oncology; some of them are Prof. P.K. Haldar Memorial Travel Fellowship, Travel Fellowship of International College of
Surgeon and many more. He was the Chairman of ICRO (Indian College of Radiation Oncology). Now he is the National President AROI (Association of Radiation Oncologist of INDIA).

His academic achievement is he is the visiting professor of Radiotherapy M.S. Ramaiah Medical College, affiliated to RGUHS, Bangalore. He is training post graduate students in M.D. Radiation
oncology and guide to Phd. Students. He is recognized professor in NATIONAL BOARD OF EXAMINATIONS. He has many publications in National and International Journals. He is the Medical Director of HCG Group of hospitals.

American Radium Society, Houston, United States

IAEA, Vienna, Austria

Institute of Southern Switzerland, Bellinzona, Switzerland

Dr. Franco Cavalli

Franco Cavalli, M.D., F.R.C.P. (London), born 1942, is Scientific Director of the Oncology Institute of Southern Switzerland (IOSI) which has its main location in Bellinzona (Switzerland), but connects all the public hospitals of the Italian speaking part of Switzerland. He has created this Institute, which encompasses medical oncology, radio-oncology, nuclear medicine, palliative care, hematology and an important research division. He is Professor (Titularprofessor) of medical oncology at the Medical Faculty in Bern (Switzerland). He has an international reputation for the treatment of and research into malignant lymphoma. He is also organizing every second year in Lugano the International Conference on Malignant Lymphoma, which is the most important congress on that topic worldwide. He has been very active also in the field of the clinical evaluation of new drugs. On that field he was chairman of the Early Clinical Trials Group of EORTC and created the SENDO (Southern Europe New Drug Organization), a conglomerate which includes IOSI and the main cancer institutes in Milan. The quality of his work has been recognized by the award of 21 national and international prices, including the Petzcoller award for special dedication to oncology and the Montaigne price. He has published more than 500 articles in peer-reviewed journals, has contributed to many books on cancer including the Textbook of Medical Oncology, which he is editing together with profs S. Kaye (London) and H.H. Hansen (Copenhagen).

He was Founding Editor and Editor-in-Chief of Annals of Oncology, Europe’s premier medical oncology journal, from 1990 to 2000 and he is on the Editorial Board of several other journals. He has founded in 1996 the International Extranodal Lymphoma Study Group (IELSG, www.ielsg.org), which encompasses now more than 200 institutions in 4 continents. IELSG is the leading cooperative group in the field of the biological and clinical studies in the field of extranodal lymphomas.

Franco Cavalli has been President of the Swiss Cancer League and is Chairman of the scientific committee of the European School of Oncology (ESO). He has been president of the International Union Against Cancer (UICC) between 2006 and 2008.

He has been member of the Swiss Parliament between 1995 and 2007.

Latin American and Caribbean Society of Medical Oncology, Buenos Aires, Argentina

Dr. Eduardo Cazap

Eduardo Cazap MD, PhD is the founder and first President of the Latin American & Caribbean Society of Medical Oncology (SLACOM) and in 2008 was elected by the General Assembly of the International Union against Cancer (UICC-Geneva) as President for the 2010-2012 period. Board Member of the American Society of Clinical Oncology (ASCO-Alexandria), representing the international members during the term 2009-2012. In 2013 Dr Cazap received the Distinguished Achievement Award of the Conquer Cancer Foundation (USA) and bestowed as Fellow of the American Society of Clinical Oncology (FASCO).

Dr. Cazap has a vast in-country and international experience and is a regular plenary speaker, chair or moderator at global cancer and health meetings as well as part of organizing major international conferences.

He is the chairman or co-chairs numerous groups and initiatives including the International Clinical Trials Working Group (ICTWG) of ASCO, the Executive Committee of the Breast Health Global Initiative (BHGI) which is co-sponsored by the Fred Hutchinson Cancer Research Center and Susan G. Komen for the Cure®, the Working Group on Cancer European Union- Latin America Health Project (EU-LAC Health Project), Scientific Council of the International School of Senology of the Senologic International Society (SIS), Strasbourg, France as well as Expert of the World Oncology Forum (WOF) of the European School of Oncology (ESO); Lugano, Switzerland.

In September 2010 he was designated by the Argentinean government member of the Executive Board of the newly created National Cancer Institute of Argentina (INC). His most recent designation is as Deputy Chair of the Developing Countries Task Force of the European Society for Medical Oncology (ESMO). He is also a Member of the Working Group to Facilitate International Cooperation in Non-Commercial Clinical Trials, Organisation for Economic Co-operation and Development (OECD)-Global Science Forum.

Koren Society for Radiation Oncology, Seoul, Korea, South

St. Jame's Hospital, Dublin, Ireland

Dr. Mary Coffey

My goal is the delivery of optimum care to all cancer patients receiving radiotherapy in a safe and holistic environment. In this context I established the School of Radiation Therapy at St. Luke’s Hospital (1982) and led the integration of the School into the University (1993). I established the first European committee for radiation therapists within the European Organisation for Research and Treatment of Cancer (EORTC), was co-founder of the Radiation TherapisT Committee within the European Society for Therapeutic Radiology and Oncology (ESTRO) and a member of the first Council of the Irish Institute of Radiography and Radiation Therapy (IIRRT) where I held Secretary and President positions. I am currently a member of the Board of the ESTRO. I was a member of the Department of Health and Children’s working party which developed the national plan for radiation oncology in Ireland. I have worked extensively with the ESTRO and the International Atomic Energy Agency (IAEA) to improve educational standards and quality of care through programmes aimed to train the trainers, incident reporting and learning and clinical audit. I was one of the founder members of the Radiation Oncology Safety Information System (ROSIS) an international voluntary reporting and learning system for radiotherapy.

Awards: ESTRO Emmanuel van der Schueren medal (2009), the first Fellowship in Radiation Therapy the Irish Institute of Radiography and Radiation Therapy (2007), the Gunilla Bental award for service to Radiotherapy awarded by the Indian Association of Radiation Therapists (2006) and the ESTRO Honorary Physicist (2013).

NCI, Bethesda, United States

The Lancet Onocology, London, United Kingdom

Dr David Collingridge has been Editor-in-Chief of The Lancet Oncology (Impact Factor, 25•1) since March, 2002, after 6 months in the role of Senior Editor. He is also the Publishing Director for The Lancet’s portfolio of specialty journals. Prior to his appointments at The Lancet, he gained a PhD in Tumour Biology from the Gray Cancer Institute/University College London, UK, and held research posts in the Department of Therapeutic Radiology, Yale University, CT, USA, and in the PET Oncology Group, Imperial College School of Medicine, Hammersmith Hospital, London, UK. He currently holds the position of Clinical Associate Professor of Radiation Medicine, at Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA.

Sociedad Chilena de Radioteripia, Temuco, Chile

ALATRO, Argentina

Johns Hopkins University, Baltimore, United States

Liverpool and Campbelltown Hospitals, Sydney, Australia

Professor Geoff Delaney is a staff specialist in Radiation Oncology at Liverpool and Campbelltown Hospitals and until recently was the Director of Cancer Services for Sydney South West Local Health District. Professor Delaney’s main tumour site interest is breast cancer. He also has research interests in health services-based research, minimising radiation error, the implementation of multidisciplinary care and health service delivery inequities in radiation therapy. He has published research in the international literature (over 120 peer-reviewed papers, reports and book chapters) and presented scientific papers and posters at national and international meetings. Professor Delaney has had significant involvement in policy decision making and planning of services through a number of committee responsibilities ranging from those at the hospital level through to State and National Oncology initiatives. These include committees for the National Breast and Ovarian Cancer Centre, NSW Cancer Institute, NSW Department of Health, Federal Government Department of Health and Ageing, Royal Australian and New Zealand College of Radiologists, NSW Cancer Council, Liverpool Hospital Health Services Executive and the Sydney South West Area Health Service Clinical Council. He has also been involved in the investigation of radiotherapy incidents at two hospitals.

Harvard University, Boston, United States

Peter Maccallum Cancer Centre, East Melbourne, Australia

Harvard University, Boston, United States

Egypt

Professor Dr. Ahmed Elzawawy is the President of AORTIC ( African Organization for Research and Training in Cancer, incorporated in New York, USA & Cape Town, South Africa www.aortic-africa.org ) , President of ICEDOC’s (International Campaign for Establishment and Development of Oncology Centres , Texas , USA www.icedoc.org & www.icedoc.net ) Experts in Cancer Without Borders , Co-President and Director of SEMCO (South and East Mediterranean College of Oncology, www.semco-oncology.info) , Coordinator of The Win-Win scientific initiative (http://www.icedoc.org/winwin.htm) that aims at increasing affordability of better value cancer treatment in the world via scientific approaches, Member of The ESMO ( European Society of Medical Oncology) Committee for Emerging Countries , Member of GTFRCC ( Global Task Force for Radiotherapy in Cancer Control), Founder and Co-Chair of the Africa Cancer Economics-Network ( ACE-Network), and Advisor to Oxford Cancer Solutions (http://www.oxfordcancersolutions.com/about/our-network). He is also a member of the Advisory Board of AfrOx , UK (www.Afrox.org). AfrOx’s mission is to partner with African countries and assist them with implementing comprehensive cancer prevention and control programmes.
Located in Egypt, Professor Ahmed Elzawawy is the Founder Professor of Clinical Oncology and Nuclear Medicine dept., Suez Canal University, Ismailia, Egypt, Senior consultant of Cancer Chemotherapy Unit, Port Said General Hospital, Egypt, and Chairman of Clinical and Radiation Oncology charity Centre, Al Soliman Hospital, Port Said, Egypt.

e-mails:worldcooperation@gmail.com & ahmedelzawawy@hotmail.com

Websites : www.icedoc.org & www.icedoc.net

Cape Peninsula University of Technology, Cape Town, South Africa

Penelope is Associate Professor and Deputy Dean at the Cape Peninsula University of Technology, with direct links to Radiation Medicine. She has 2 diplomas (radiography and radiation therapy), a BSc Hon (Radiotherapy), an MSc (Medical Physics) and a DTech (Radiography: Professional Education). She has a Teaching Diploma, a Post Graduate Certificate in International Research Ethics and a Counselling Certificate. Penelope is chairperson of the Faculty Research Ethics Committee and the Senate Ethics Committee, a Senator and member of the Higher Degrees Committee. She has extensive experience in radiation oncology and radiation therapist education on the African continent through her involvement with the IAEA, appointment as an external examiner in Africa and networking. Penelope is involved in academic endeavours to develop the profession. Her most recent publications are; Kyei and Engel-Hills (2013) A pain survey to support role development for the radiation therapist in Ghana. Journal of Radiotherapy in Practice, 12 (2) and Winberg, Engel-Hills, Jacobs and Garraway (2013) Professionally-oriented knowledge and the purpose of professionally-oriented higher education. In: Kagisano: The Aims of Higher Education, Number 9. Her most recent conference presentation is; Rosenblatt, Woldemariam, Tigeneh, Prasad, Engel-Hills & Ndlovu (2013). Radiotherapy Education in Africa: an IAEA/AFRA survey. AORTIC. 9th International Conference on Cancer in Africa. She is currently the recipient of two research grants for research in student retention and ethics in the curriculum. Penelope lives in Cape Town with her husband and daughter.

Current Positions:
Chairperson – Health Sciences Research Ethics CommitteeChairperson – Senate Ethics Committee
Editorial Team Member – South African Radiographer
International Editorial Board – Journal of Radiotherapy Practice
Reviewer – Radiography

IAEA, Vienna, Austria

Maria Manuela (Nelly) Enwerem-Bromson holds a Bachelor of Arts Degrees in Political Science and African Studies from Wellesley College, USA and a Master of Arts Degree from the Fletcher School of Law and Diplomacy, also in the USA. Prior to joining the IAEA in January 2014, Nelly Enwerem-Bromson worked in strategic policy development, partnerships and resource mobilization at the World Health Organization for 11 years, in its regional offices for Africa and South-East Asia, as well as at Headquarters in Geneva. Nelly Enwerem-Bromson came to the United Nations after years in national service, as adviser to the President, the Attorney-General and the Minister of State Reform of Portugal. She has also worked as an international investment banker in London and a Professor of International Relations and Development.

University of Toronto, Toronto, Canada

I am a medical oncologist (Fellow of the Royal College of Physicians and Surgeons of Canada) and scientist with a focus in global cancer control and women’s health equity. My current academic appointments include: Scientist, Women’s College Research Institute; Assistant Professor, Department of Medicine, Faculty of Medicine and the Division of Public Health Policy, Dalla Lana School of Public Health at the University of Toronto; Adjunct Professor, James P Grant School of Public Health, BRAC University, Dhaka Bangladesh, and Assistant Professor, Department of Oncology, Queen’s University Kingston Ontario. Since 2004, I have developed a program of research and training in global breast cancer care and control, with projects and field work in Canada, Vietnam and Bangladesh. The overarching aim of my work is to inform best practices to reduce health inequities for under-served women with cancer.

From 2009-2011, I served as (volunteer) Deputy Scientific Director for the International Breast Cancer Research Foundation (www.ibcrf.org Madison, WI). In collaboration with the IBCRF I co-founded a small breast cancer clinic in Khulna Division, Bangladesh, and received a Rising Stars in Global Health award from Grand Challenges Canada to support my community-based breast cancer “mHealth” project.

More recent appointments include: the editorial board of the Journal of Cancer Policy (Elsevier, UK); Advisor to the National Institute for Cancer Control of Vietnam; the Technical Advisory Committee of the Global Task Force on Expanded Access to Cancer Care and Control (GTF.CCC of the Harvard Global Equity Initiative, Boston); the Global task Force on Radiotherapy for Cancer Control (UICC, Geneva); and was invited to join the faculty of the Institute of Cancer Policy, King’s Health Partners, London http://www.instituteofcancerpolicy.org/

Follow Ophira @OphiraG and

http://www.linkedin.com/pub/ophira-ginsburg/15/b7/2a1

Indonesian Radiation Oncology Society, Jakarta, Indonesia

Soehartati Gondhowiardjo, MD, PhD is currently a Radiation Oncologist
and the Head of Radiotherapy Department at Cipto Mangunkusumo
National General Hospital (RSCM) Jakarta, and also an active teaching
staff at her alma mater, the Faculty of Medicine University of Indonesia
in Jakarta since 1995.

She earned her medical degree in 1980, received her certification as a
radiologist in 1987 and studied Radiation Oncology in the
Strahlentherapie Abteilung Wilhelm-Waestfaelichen, Universitaet
Muenster – Germany in 1988. In 1998, she had her Doctoral Degree
after finishing her study on EBV and cell proliferation activity of
nasopharyngeal as predictive factors of nasopharyngeal cancer (NPC)
radiation responses, and was appointed as a Professor on Radiation
Oncology in 2005.

Her research activities include several topics in radiation oncology
physics and molecular oncology and have resulted in several
publications in the oncology literature and books, both as contributor or editor. Her current fields of interest include Breast Cancer, Stereotactic, CNS Tumors, and Head & Neck Cancers; for which she has been actively sharing her expertise with her colleagues in numerous national oncology forums.

She is currently actively participating in several organizations of
oncology professionals. She is the President of the Indonesian
Radiation Oncology Society (IROS/PORI), the Immediate Past
President of the South East Asian Radiation Oncology Group
(SEAROG), the Immediate Past President of the Indonesian Society for
Oncology (ISO/POI), Council Member of the Asian Clinical Oncology
Society (ACOS) and a member of the European Society for
Radiotherapy and Oncology (ESTRO) and Pediatric Radiation Oncology
Society (PROS).

In addition to organizational, clinical, and research works, she is also
responsible as the National Project Coordinator for several IAEA
projects, including Transition from 2D to 3D to Intensity Modulated
Radiotherapy (IMRT), Stereotactic Body Radiotherapy (SBRT) and
Quality Assurance in Radiotherapy (QUATRO).

University of Toronto, Toronto, Canada

Mary Gospodarowicz is the current President of UICC. She is Medical Director of the Princess Margaret Cancer Centre at the University Health Network in Toronto, Canada and Regional Vice-President of Cancer Care Ontario for Toronto South. She recently completed a 10 year term as Professor and Chair of the Department of Radiation Oncology at the University of Toronto and Chief of the Radiation Medicine Program at Princess Margaret.

ESTRO, Aarhus, Denmark

University of Pennsylvania, Philadelphia, United States

Dr. Surbhi Grover is a final year resident in the Department of Radiation Oncology at the University of Pennsylvania and will be joining on faculty in the department of radiation oncology as assistant professor in July 2014. She graduated magna cum laude from Columbia University in 2004, where she earned her BA in development economics. Subsequently, she attending Harvard Medical School and earned her MD in 2009. She completed her internal medicine internship at the University of Pennsylvania in 2009 and started her residency in radiation oncology in 2010. She was also awarded Sommer scholarship for a Masters in Public Health at Johns Hopkins Bloomberg School of Public Health, which she completed in 2013.

University of Pennsylvania, Philadelphia, United States

Stephen M. Hahn, MD is the Chair and Henry K. Pancoast Professor of Radiation Oncology at the Perelman School of Medicine at the University of Pennsylvania. Dr. Hahn is an active clinician, with particular expertise in treating patients with lung, sarcoma and prostate cancers and in the use of proton therapy. Board certified in Internal Medicine and Radiation Oncology of Medicine Hahn received his medical degree from Temple University School of Medicine. In 1987, he completed his residency and served as Chief Resident of Internal Medicine at the University of California, San Francisco. He completed a Medical Oncology Fellowship and a Radiation Oncology Residency at the NCI in 1991 and 1994 respectively. Prior to joining Penn, Hahn was a Medical and Radiation Oncologist in Santa Rosa, CA. From 1993-95, he served as Chief of the NCI’s Prostate Cancer Clinic, Clinical Pharmacology Branch, in Bethesda, MD, and a senior investigator at the NCI. Hahn also served as a Commander in the NCI’s U.S. Public Health Service from 1989-95.

Dr. Hahn joined Penn in 1996 and was promoted to Associate Professor of Radiation Oncology and Medical Oncology in 2001. Dr. Hahn’s research interests include investigation of the tumor microenvironment as it relates to radiation response, the integration of targeted agents with chemoradiotherapy, photodynamic therapy particularly in thoracic malignancies, the investigative use and value of proton therapy, and the assessment of the effect of quality and safety programs in radiation oncology. Dr. Hahn is the Co-Program Leader of the Radiation Biology and Imaging Research Program in the Abramson Cancer Center of the University of Pennsylvania.

Hahn served as a permanent member of the National Cancer Institute’s Clinical Oncology Study Section from 2008-2011. He currently serves as a Senior Editor of Clinical Cancer Research and is a long standing member of the American Society for Radiation Oncology, the American Society of Clinical Oncology, the Radiation Research Society, the American Society of Photobiology, the American Association for Cancer Research, and the University of Pennsylvania’s John Morgan Society. He was elected to serve a four year term as a Trustee of the American Board of Radiology in 2013 and became a Fellow of the American Society for Radiation Oncology (FASTRO).

AAPM, United States

Queen's University, Canada

Dr. Timothy Hanna is a clinician scientist at the Division of Cancer Care and Epidemiology, Cancer Research Institute at Queen’s University, Kingston, Ontario, Canada. He is also a radiation oncologist at the Cancer Center of Southeastern Ontario. His work focuses on health services research in oncology. This has involved identifying barriers to access and quality in radiotherapy, and modeling the benefit of optimally utilized radiotherapy. Dr. Hanna recently completed a two-year fellowship at the Collaboration for Cancer Outcomes Research and Evaluation (CCORE) at Liverpool Hospital in Sydney, Australia (2010-2012). He developed models of population benefit of optimal radiotherapy utilization as part of his PhD thesis work and fellowship there, working with Prof M Barton, Prof G Delaney and Dr. J Shafiq. Prior to this, he trained at Queen’s University in Radiation Oncology and completed an MSc with Dr. WJ Mackillop, focusing on barriers to access to radiation and its impact on cancer outcomes for endometrial cancer. Dr. Hanna obtained his MD at the University of Toronto.

University College London, London, United Kingdom

Peter Hoskin is Professor in Clinical Oncology at University College London. He has been a consultant in clinical oncology at Mount Vernon Cancer Centre, Northwood UK since 1992. His research interests have ranged from palliative radiotherapy to the use of radiosensitisers and brachytherapy.

ASTRO, New York, United States

AMPO, Rabat, Morocco

Erasmus MC Cancer Institute, Rotterdam, Netherlands

Luca Incrocci is associate Professor of Radiation Oncology at the Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands. He received his M.D. in 1992 at the University of Pisa, Italy, and then joined the University Hospital Rotterdam to complete residencies in the Departments of Urology and Radiation Oncology.
His current research is mainly focused on Quality of Life of cancer patients and on the development of radiation techniques to improve treatment outcome and to decrease side effects (especially sexual dysfunction) after radiation therapy for urological malignancies.
He is actively involved in international programs to provide education and improve radiation therapy access in African countries.
Prof. Incrocci is a member of several scientific societies including the European Association of Urology, the American and European Societies for Therapeutic Radiology and Oncology and the European and International Societies for Sexual Medicine. He is a member of the Scientific Board of the Dutch Cancer Society. He is actively involved in the teaching and research of fellows and students.
Prof. Incrocci is a manuscript reviewer for a number of international journals; he is Associate Editor of the Journal of Sexual Medicine and the immediate Past-President of the International Society for Sexuality and Cancer.
Prof. Incrocci is the author of more than 80 peer-reviewed papers, reviews, and book chapters.

University of Toronto, Toronto, Canada

Dr. David Jaffray graduated from the University of Alberta, Edmonton, Alberta, Canada with a B.Sc. in Physics (Hons.) in 1988 and completed his Ph.D. in the Department of Medical Biophysics at the University of Western Ontario, London, Ontario in 1994. Following graduation, he took a position as Staff Physicist in the Department of Radiation Oncology at William Beaumont Hospital, Royal Oak, Michigan where he instigated a direction of research that garnered funding from the NIH and from congressionally-directed funding programs. Dr. Jaffray became a Board Certified Medical Physicist (ABMP – Radiation Oncology) in 1999.

In 2002, Dr. Jaffray joined the Princess Margaret Hospital in Toronto, Ontario as Head of Radiation Physics and a Senior Scientist within the Ontario Cancer Institute. Dr. Jaffray holds the Fidani Chair in Radiation Physics and is a principal in the STTARR Innovation Centre of the University Health Network. He is appointed as a Professor in the Departments of Radiation Oncology, Medical Biophysics, and Institute for Biomaterials and Biomedical Engineering at the University of Toronto. His primary area of research over the past 10 years has been in the development and application of image-guided radiation therapy. He has over 5 patents issued and several licensed, including, kilovoltage cone-beam computed tomography for image-guided radiation therapy. Dr. Jaffray has in excess of 120 peer-reviewed publications in the field, in excess of 100 invited lectures, and holds numerous peer-review and industry sponsored research grants. He sits on numerous scientific and research boards and has contributed to the NIH and CIHR grant review process for several years. He is a member at large of the Science Council of the AAPM and has an active teaching role in workshops and annual meeting of the American Society of Therapeutic Radiation Oncology (ASTRO). He has an active interest in commercialization and led the development of a variety of commercial products including software and hardware for QA and the development of small animal irradiator systems for basic research. He has successfully supervised over 20 graduate students and fellows. Dr. Jaffray has won each of the major prizes in the field of the medical physics, including, the Sylvia Sorkin-Greenfield Award, The Farrington Daniels Award, and the Sylvia Fedoruk Award. In 2004, Dr. Jaffray was identified as one of Canada’s Top 40 Under 40 and was recognized by The University of Western Ontario with their Young Alumni Award. His current research interests focus on the development of novel approaches of targeting and applying radiation therapy and translating these advances to clinical practice.

American Radium Society, Houston, United States

SH Oncology Cancer Care, Harare, Zimbabwe

Dr W Kadzatsa MD, MMed Rad Onc, Lecturer, University of Zimbabwe
He was born in Mutoko, Zimbabwe and graduated at Warsaw Medical University, Poland (2001). He specialized in Clinical Oncology (Radiotherapy and Oncology) at College of Health Sciences, University of Zimbabwe (2008).

Dr Kadzatsa is a member of a number of scientific societies including ASCO, ESTRO, AFROG and ARROZ.

His clinical research focuses on HIV related malignancy, head and neck cancers and prostate cancer. He has major interest in radiobiology and physics.

Varian Medical Systems, Palo Alto, United States

AFROX, Oxford, United Kingdom

AFROG, Kampala, Uganda

Memorial Sloan-Kettering Cancer Center, New York, United States

I am a junior investigator who was appointed to the staff at Memorial Sloan-Kettering Cancer Center (MSKCC) on the Hepatopancreatobiliary Surgery Service in August, 2010. Prior to my appointment I completed a two-year fellowship in surgical oncology at MSKCC. I am also co-founder of a non-profit organization called Surgeons OverSeas (SOS). Since 2001 I have been collaborating with surgical colleagues in sub-Saharan Africa working on surgical oncology and general surgical development projects. My early research demonstrated the importance of surgery as a component of public health. Now, my research is focused on defining disparities in cancer care, cancer outcomes, and surgical oncology training in low- and middle-income countries. After documenting the differences in metastatic presentation of patients with colorectal cancer in Nigeria, prospective studies exploring these differences and community based screening projects for colorectal cancer are underway in West Africa. We have also formed a consortium of investigators in 4 hospitals in Nigeria centered on gastrointestinal malignancies. This project will create a clinical, pathologic, and radiologic database. I have mentored and trained surgeons from Nigeria, Sierra Leone, Ghana, and Malawi.

Harvard University, Boston, United States

Peter MacCallum Cancer Centre, Melbourne, Australia

UICC, Turkey

Graduated from Hacettepe University Medical School Ankara-Turkey in third rank among graduates in 1981. Postdoctoral fellow and Fullbright scholar at MD Anderson Cancer Center USA (1992-94). Editor of Turkish Journal of Cancer. Member of SIOP, ASCO, International Children’s Center. He had served as a leading healthcare executive at Hacettepe University; Vice-Director of Children’s Hospital (1997-1998), the Director of Oncology Hospital (1999-2007), Director of Children’s Hospital (2000-2007) and President of Institute of Child Health (2000-2004), President of Institute of Oncology (2004-2008), Board Member of Institute for Health Sciences (2000-2007), Member of Senate (2000-2011) & CEO of Hacettepe University Hospitals (2008-2011). 

He has 150 publication in peer reviewed international scientific journals and 1100 citation in international medical Journals and numerous abstracts in international meetings.



He also has a long term experience on NGO management; “UICC-International Union for Cancer Control – Board Member – Geneva – Switzerland (2008 – 2012)” “President of Turkish Association for Cancer Research and Control, Ankara-Turkey (2004-2012)”, “President of European Cancer Leagues-ECL – Brussels-Belgium (2009-2011)”, “President of Turkish National Pediatric Society (2009-2012)”, “President of Turkish Pediatric Oncology Group (2011-2013)”. His experience on healthcare management during the last 15 years brought him to the top of the Hacettepe University Hospitals as CEO between 2008-2011.

He recently elected as the President Elect of UICC for the term of 2012-2014.

University of Hong Kong-Shenzhen Hospital, Hong Kong

Dr. Lee was the Chief of Service of the Department of Clinical Oncology in Pamela Youde Nethersole Eastern Hospital from 1994 to 2012. She has been Honorary Clinical Professor in Clinical Oncology, University of Hong Kong since 2009. After retiring from public hospital in Hong Kong, she has now taken up the new post as the Chief of Service for the Center of Clinical Oncology at the University of Hong Kong-Shenzhen Hospital in China.
In addition to her professional qualification as Fellow of the Royal College of Radiologists in Clinical Oncology (United Kingdom) and Fellow of the Hong Kong Academy of Medicine, she was conferred Doctor of Medicine by the University of Hong Kong in 2008, and was awarded the Sir Patrick Manson Gold Medal.
She has been the President of Hong Kong Head and Neck Society and Chairman of Hong Kong Nasopharyngeal Cancer Study Group. Currently she is the Vice President of Hong Kong College of Radiologists and the Vice Chairman of Hong Kong Anti-Cancer Society.
Dr. Lee’s main research contributions focus on nasopharyngeal cancer. She serves in editorial board of many international journals. She also serves in many international academic organizations, including being the Coordinator of the Global Advisory Group and a member of TNM Expert Advisory Panel on Head and Neck Cancers for the Union for International Cancer Control, and a Faculty Member on Nasopharyngeal Cancer for the European Society of Medical Oncology.
Dr. Lee has received many honors. She was awarded Gilbert H. Fletcher Distinguished Professor Lecturer by The University of Texas, M.D. Anderson Cancer Center in 2009, Honorary Membership by the European Society for Radiotherapy & Oncology in 2012 and Honorary Membership by the Radiological Society of North America in 2013.

Trinity College, Dublin, Ireland

Michelle Leech is Associate Professor and Head of the Discipline of Radiation Therapy, School of Medicine, Trinity College, Dublin, where she directs the BSc. (Honours) Radiation Therapy and MSc. Advanced Radiotherapy Practice, as well as leading the Discipline’s Advanced Radiation Therapy Trinity Research group (ARTT).

Michelle is current Chair of the Radiation TherapisT (RTT) Committee within ESTRO, member of the Scientific Council, and ESTRO Education and Training Committee as well as being course director of the ESTRO basic treatment planning course and a faculty member of the ESTRO/IAEA project on training the RTT trainers.

University of Gent, Gent, Belgium

ALATRO, Guatemala City, Guatemala

University of Toronto, Toronto, Canada

I have been a radiation oncologist clinician-scientist since 1988, and have established a mature research program focused on several aspects of translational molecular oncology, including the development of biomarkers for head and neck cancers, high-throughput screens to identify novel anti-cancer therapeutics, and stem cell regenerative therapy. I am the Chief of the Radiation Medicine Program at the Princess Margaret Cancer Centre, Senior Scientist at the Ontario Cancer Institute, and Professor in the Departments of Radiation Oncology (Chair), Medical Biophysics and Otolaryngology, at the University of Toronto. I also hold the Dr. Mariano Elia Chair in Head & Neck Oncology

AMPATH/Indiana University, Indianapolis, United States

University of California- LA, Los Angeles, United States

Dr. Daniel Low, Ph.D. is a professor and the Vice Chair of Medical Physics in the Department of Radiation Oncology at UCLA. He has been a medical physicist for more than 25 years, written more than 170 peer-reviewed manuscripts and been the principal investigator on 5 R01 grans from the United States National Institutes of Health. His research interests include advanced radiation therapy quality assurance techniques and breathing motion modeling and applications. Dr. Low is certified in radiation therapy physics by the American Board of Medical Physics and the American Board of Radiology and is a Fellow of the AAPM.

University of Toronto, Toronto, Canada

Miller MacPherson joined the Radiation Medicine Program at Princess Margaret Cancer Centre in 2008. From 2008-2013 he was Head of Physics at the Carlo Fidani Peel Regional Cancer Centre at Credit Valley Hospital in Mississauga, Ontario. His work at the Princess Margaret includes ongoing contributions to international activities.

Queen's University, Kingston, Canada

IAEA, Vienna, Austria

Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

Ben Mijnheer got his PhD in 1971 at the University of Amsterdam. Upon completion of his postdoc at the Central Bureau of Nuclear Measurements of Euratom in Geel, Belgium, he was appointed as research fellow on the neutron therapy project in the Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital (NKI-AVL) in Amsterdam. In 1981 he joined NKI-AVL as a clinical physicist, and is until now involved in various research projects and teaching activities in the Department of Radiation Oncology. In 1986 he was a visiting scientist in the Joint Center for Radiation Therapy of Harvard Medical School in Boston, USA, studying the dosimetric aspects of a variety of advanced (computer-controlled) treatment techniques. After his return he was responsible for the physics research and training at the NKI-AVL. His main research activities were in the field of dosimetry of ionising radiation, the development of new irradiation techniques, and quality assurance of radiotherapy. It was the era in which the NKI-AVL performed pioneering work in the design of 3D conformal radiotherapy (3D CRT) techniques, which upon further development become IMRT.

In 1994 to 2001 he was the head of Clinical Physics and Instrumentation. From 2003 to 2009 he was professor Medical Technology in Oncology at Inholland University of Professional Training. He was the first physics editor of Radiotherapy and Oncology, and (co-)-author of about 250 articles and chapters in books, received approximately 20 personal research grants, and was supervisor of about 25 PhD theses. He is fully engaged in education and was a founding faculty member of the ESTRO “The Leuven course” from 1985 to 1997, and course director of the ESTRO Teaching Course on IMRT and Other Conformal Techniques in Practice (“The Amsterdam course”) from 1996 to 2006. He was also involved in numerous other courses dealing with various aspects of radiotherapy for medical physicists, radiation oncologists and radiation therapy technologists, both at the national and international level. He received the ESTRO Breur Gold Medal Award in Edinburgh in 1998 and the ESTRO Emmanuel van der Schueren Award in April 2013 in Geneva.

University of Toronto, Toronto, Canada

University of Sydney, Sydney, Australia

I am a recently retired Radiation Oncologist who has developed an interest in developing Radiotherapy and Cancer Services in SE Asia and Pacific Islands.

My involvement has been through two groups at University of Sydney;
(a) the Hoc Mai Foundation in Viet Nam and
(b) the Office for Global Health that covers most of SE Asia.

I have also established the Asia Pacific Radiation Oncology Special Interest Group (APROSIG) through the RANZCR – Faculty of Radiation Oncology that works with other SIGs in the Australian and New Zealand Colleges of RTTs (AIR) and ROMPs (ACPSEM) in providing volunteers funded through AusAID to work for 6 to 12 months in Radiotherapy Departments in SE Asia.

The countries of contact include Papua New Guinea, Malaysia, Viet Nam, Cambodia, Bangladesh and Nepal, with future interest in Sri Lanka and Myanmar.

This has given a practical insight into the ‘problems’ in Low Income Countries who deserve special support from the GTFRCC.

Japanese Society for Radiation Oncology, Gunma, Japan

University of Toronto, Toronto, Canada

George W. Bush Institute, United States

Dr. Oluwole, MD, MRCP, FWACP, FRCP (Pediatrics), is the founding Executive Director of Pink Ribbon Red Ribbon at the George W. Bush Institute. She leads the global efforts of this public-private partnership to fight cervical and breast cancers in developing countries.

Prior to assuming this role, she was the Director of the Center for Health Policy and Capacity Development at FHI360 and the Project Director for the Africa’s Health in 2010 project for six years. In that position, she managed a multi-million dollar project and empowered African institutions/governments to plan, manage and evaluate effective and tailored health programs, including maternal, newborn and child health, family planning, nutrition, infectious diseases, health systems strengthening and gender/gender-based violence. She has nurtured partnerships with a spectrum of African government, institutional, and donor partners.

Before Africa’s Health in 2010, Dr. Oluwole spent 25 years as a public health practitioner across Africa, including 10 years of management responsibility at the regional level and as a country WHO Representative. As the former Director of the Division of Family and Reproductive Health with the WHO Regional Office for Africa (WHO/AFRO), she managed a team of more than 100 while providing strategic vision, outstanding leadership, and effective advocacy in developing and implementing significant regional reproductive, women’s and maternal/newborn health strategies, including a focus on community-based approaches for women’s, maternal, newborn, and child health and renewed efforts to address pediatric AIDS and PMTCT issues. Dr. Oluwole has been widely published and is a sought-after public speaker on topics ranging from newborn health to women’s health to health systems strengthening. She began her career as a pediatrician and a professor of pediatrics in her native Nigeria. She holds an MD with Honors from the University of Lagos, and a Membership of the Royal College of Physicians (MRCP/Pediatrics) from University of Edinburgh/Royal College of Physicians in the UK, where she is also a Fellow, and a Fellowship of West African College of Physicians.

ESTRO, Tilburg, Netherlands

Dr. Philip Poortsman (MD, PhD) is the current President of the European Society of Radiation Oncology (ESTRO) and a radiation oncologist at the Institute Verbeeten in Tilburg, the Netherlands where his interests are in breast cancer, quality assurance in clinical trials, malignant lymphoma and rare tumours. He is actively involved in education and training programs at ESTRO as the course director of the “Multidisciplinary Management of Breast Cancer” and core member of the Educational and Teaching Committee at ESTRO. He is also the Quality Assurance officer of the Radiation Oncology Group in EORTC.

After completing his medical studies at the University of Antwerp, in 1986, Dr. Poortmans was trained as a radiation oncologist at the Middelheim and Vincentius Hospitals in Antwerp under the supervision of colleagues including Walter Van den Bogaert, Guy Langerock, Anne Strubbe, Allan Van Oosterom, Daniëlle Van de Weyngaert and Pierre Scalliet. He completed his Ph.D. thesis on quality assurance in clinical trials in breast cancer in 2005 at the University of Maastricht with Philippe Lambin and Walter Van den Bogaert as promoters. He was granted an honorary membership of BVRO/ABRO in 2012 and was nominated as “Toparts” (Outstanding doctor) by the Dutch radiation oncologists in 2011 and 2012.

University of Turin, Turin, Italy

Dr. Ricardi is currently Full Professor of Radiation Oncology at University of Turin and Chairman of Radiation Oncology Department at the San Giovanni Battista University Hospital in Turin, Italy.
Dr Ricardi graduated in Medicine at the University of Turin in 1987, completed his residency training in Radiation Oncology (1991) and Medical Oncology (1995) at the same University.
Following a fellowship at St. Jude Children’s Research Hospital in Memphis, he was the head of Pediatric Radiation Oncology program in Turin since 1997.
In 2002, Dr. Ricardi has been appointed as chairman of Radiation Oncology Department and Associate Professor in Radiation Oncology at the University of Turin, becoming Full Professor in Radiation Oncology at the same University in 2006.
Dr. Ricardi’s main areas of clinical and scientific interest include lung cancer, lymphoma, childhood tumors, central nervous system tumors. He is also an expert in the development of cutting edge technologies in Radiation Oncology (radiosurgery, stereotactic ablative radiation therapy, image-guidance, volumetric IMRT).
Dr. Ricardi has authored more than 100 full research papers, over 400 abstracts and participated as invited speaker in a number of national and international conferences. He is active in many educational activities, both at national and international level.
Dr. Ricardi is also a member of numerous national and international scientific societies, such as the Italian Association of Radiation Oncology (AIRO: he is currently the President of its Scientific Committee), the European SocieTy for Radiation and Oncology (Board of Directors from 2004 to 2006; Executive Administrator from 2006 to 2011; now Chair of ESTRO National Societies Committee), the EORTC Radiotherapy Group.
In 2007, Dr. Ricardi was appointed to the Ministry of Health’s National Oncological Commission.
Dr. Ricardi has continued to promote and participate in cooperative research projects, both nationally and internationally.

University of Toronto, Toronto, Canada

IAEA, Vienna, Austria

Eduardo Rosenblatt is a radiation oncologist and Section Head of the Applied Radiation Biology and Radiotherapy Section, Division of Human Health, International Atomic Energy Agency in Vienna. Dr. Rosenblatt has published extensively on worldwide radiation therapy capacity.

IACR, Lyon, France

Yonsei University College of Medicine, Seoul, Korea, South

Professor Jinsil Seong, MD PhD, currently works at Department of Radiation Oncology, Yonsei University College of Medicine, Seoul. Prior to her current position, she has been a Visiting Scientist in Department of Experimental Radiotherapy, M.D. Anderson Cancer Center, Houston, USA. She graduated from Yonsei University College of Medicine, Seoul and subsequently completed her PhD degree from Yonsei University, Seoul.

Professor Seong is a former President of Yonsei Liver Cancer Study Group and also a member of various national and international societies including International Liver Cancer Association, Korean Liver Cancer Study Group, European Society for Therapeutic Radiology and Oncology and American Society for Therapeutic Radiology and Oncology. She served as a member of the Editorial Board of International Journal of Radiation Oncology Biology Physics for the past 10 years. Currently she is a council member of Asian Clinical Oncology Society as well as Asia Pacific Primary Liver Cancer Expert Meeting. She is also working as a consultant in International Atomic Energy Agency. She has been awarded many times for her credit including Korean Cancer Association Distinguished Scientific Award (2012), Best Presentation Award (bronze) in 2nd Asia Pacific Primary Liver Cancer Expert Meeting (2011) and Young Investigator Award in International Congress of Liver Disease (2004). She has published 93 articles in non-SCI listed journals and 100 articles in SCI listed journals. She has also delivered 106 talks at major national and international congresses. Research interest is “Radiotherapy of HCC” in clinical approach as well as in translational research.

Cancer Care Ontario, Toronto, Canada

Kings College London, London, United Kingdom

Richard Sullivan is Professor, Cancer Policy & Global Health at Kings College London and founding director of the new Kings Institute of Cancer Policy. Richard is an executive member of the Kings Health Partners Cancer Centre and is Visiting Professor at the Faculty of Medicine, Universidad Catolica, Chile. Richard also serves on the Centre for Global Health at Kings and the Marjan Centre for Conflict & Conservation.

Richard qualified in medicine at St. Marys Hospital, London. Following training in surgery he completed a PhD in cell signalling at University College London. After a period in the pharmaceutical industry he then spent nearly a decade with one of the worlds largest cancer research NGO’s Cancer Research UK as their clinical director. There he led on a number of major strategies including the UK’s Experimental Cancer Medicine Centres Network, and the development of the European Comprehensive Cancer Centres program. In 2008 Richard moved to the London School of Economics were he studied complex healthcare systems within the health, society and population programme working on conflict and post conflict public health settings in the Balkans, Africa and the Middle East, before joining Kings College London in 2010.

Richard serves on a wide variety of international boards, and is past UK Director of the Council for Emerging National Security Affairs (CENSA) a national security think-tank where he specialised in counter-proliferation and the security implications of global health. Richard’s research programmes focus on two areas: global cancer policy and conflict & health focusing on public health systems in high-risk, conflict areas focusing on DR Congo, Afghanistan & Libya. He leads a number of programs including studies of the basic package of health services in Afghanistan, armed violence reduction and public health and the relationship between security and global health. In global cancer public policy Richard has led a number of major Lancet Oncology Commissions e.g. affordability of cancer in high-income countries, global childhood cancer care and most recently cancer care in Latin America. And is currently a Lancet Commissioner leading cancer aspect of the Global Surgery review and also lead for the India and Cancer Series shortly to be published.

University of Pennsylvania, Philadelphia, United States

National Cancer Center Singapore, Singapore

NIH, Bethesda, United States

University of British Columbia, Vancouver, Canada

ECCO, Leiden, Netherlands

Western University, London, Canada

Jake Van Dyk, MSc, FCCPM, FAAPM, FCOMP, DSc, is Professor Emeritus of Oncology and Medical Biophysics, at Western University, London, Ontario, Canada, and former Manager (Chief) of Physics and Engineering at the London Regional Cancer Program (LRCP). He has over 40 years of experience in the practical facets of radiation oncology physics with 24 years at the Princess Margaret Hospital (PMH) in Toronto, Ontario, Canada; 15 years at the LRCP; and about 20 months at the International Atomic Energy Agency (IAEA), Vienna, Austria. His research includes multiple aspects of the implementation of modern technology into clinical practice as well as assessing normal tissue response with special emphasis on radiation-induced lung damage. He has won various teaching awards. He was elected Fellow of the American Association of Physicists in Medicine in July 1997 for his “contributions to the field of medical physics”. In 2011, he was awarded the Gold Medal by the Canadian Organization of Medical Physicists (COMP). In July 2012, he was presented with COMP’s inaugural Fellow of COMP (FCOMP) award in recognition of “his significant contribution to the organization and to the field of medical physics in Canada”. In 2013, in view of the 50th anniversary of the International Organization of Medical Physicists (IOMP), he was selected as one out of 50 medical physicists world-wide “who have made an outstanding contribution to the advancement of medical physics over the last 50 years.” He has served as the President of the Canadian College of Physicists in Medicine (CCPM). He participates as a consultant and lecturer for the IAEA. In addition to about 200 publications, he has published 3 volumes (~2100 pages) on “The Modern Technology of Radiation Oncology: A Compendium for Medical Physicists and Radiation Oncologists”. In May 2014, Western University conferred on him an honorary doctorate.

NIH, Bethesda, United States

Bhadrasain Vikram is Chief of the Clinical Radiation Oncology Branch at the NCI (Bethesda, MD) overseeing a portfolio of clinical research grants within the Radiation Research Program as well as assisting the Cancer Therapy Evaluation Program and the Coordinating Center for Clinical Trials with NCI’s cooperative clinical trials groups program.

Uruguay

Dr. Tabaré Vázquez is a radiation oncologist and statesman. Dr. Vazquez attended medical school at Uruguay’s Universidad de la República and graduated with a specialty in oncology and radiology in 1972. In 2004, Dr. Vazquez was elected President of the Oriental Republic of Uruguay and served for five years beginning March 1, 2005. Even as president, Dr. Vázquez continued his practice, dedicating one morning a week to a Montevideo clinic

IARC, Lyon, France

Ingham Institute for Applied Medical Research, Sydney, Australia

Dr. Mei Ling Yap MBBS BSc (Med) FRANZCR is a staff specialist radiation oncologist at Liverpool and Macarthur Cancer Therapy Centres, Sydney, New South Wales, Australia. Her clinical training was undertaken across Sydney, Australia and National University Cancer Institute, Singapore. Dr Yap’s clinical interests include lung, breast and gynecological cancers, which she developed during a clinical research fellowship with the University of Toronto and Princess Margaret Cancer Centre, Canada.

One of Dr Yap’s major research interests is the optimal utilization of radiotherapy in low and middle-income countries, an ongoing project with the Collaboration of Cancer Outcomes, Research and Evaluation (CCORE) team at the Ingham Institute for Applied Medical Research. She holds conjoint lecturer appointments with the University of New South Wales and the University of Western Sydney. Dr Yap is the Australasian representative on the membership committee of the International Association for the Study of Lung Cancer (IASLC).

Therapeutic Radiology and Oncology Committee of Chinese Anti-Cancer Association, Shandong, China

IAEA, Vienna, Austria

Graduated in 1980 from Buenos Aires University, he finished his specialization in Radiation Oncology in 1985. He moved to Uruguay in 1989, to work in Dr. Leborgne’s department.

He continued his training as fellow in the Mallinckrodt Institute of Radiology, Washington University in Saint Louis, with Carlos Perez and Perry Grigsby in 1995.

His major fields of interest are gynaecology, H&N, QA, health economics, and clinical radiobiology, in which he has published his work with Felix Leborgne, Jack Fowler and Jolyon Hendry.
He began his involvement with the International Atomic Energy Agency – IAEA as expert and lecturer in 1993. He joined the Applied Radiation Biology and Radiotherapy Section of the Agency in 2004.
He has contributed to many Agency publications, and has been involved in the organization of QUATRO audits and expert missions, technical meetings, as well as training activities in Asia, Europe, Africa and Latin America.

He has been involved in 99 radiotherapy projects worldwide as technical adviser, in 7 research studies as principal investigator, and is responsible for the Radiation Oncology Section of the IAEA – Human Health Campus website.

He is part of the IAEA Advisory Group on increasing access to Radiotherapy Technology in low and middle income countries (AGaRT), the Global Quality Assurance of Radiation Therapy Harmonisation Group, and the ESTRO – HERO (Health Economics in Radiation Oncology) Task Force, as IAEA representative.